ECORCE: Tolerance Assessment of Tailored 3d-printed TFO With Silicone Interface for the Treatment of Post-burn Face Scar

Sponsor
Centre Hospitalier Régional Metz-Thionville (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04884789
Collaborator
(none)
13
1
52

Study Details

Study Description

Brief Summary

The purpose of this study is to assess the tolerance of tailored 3d-printed transparent face orthosis used in the medical care of post-burn face scar.

Condition or Disease Intervention/Treatment Phase
  • Device: COFIS 3D
N/A

Detailed Description

Burn injuries are not a rare affection. According to WHO (World Health Organization), in 2004 there were 11 million peoples in the world who were affected by burn injuries caused by fire and who needed medical cares. This important number ignores non-fire thermal, chemical and electrical burns. Face is one of the most susceptible areas of burn where the prevalence was reported to be 6-60%.

Hypertrophic scars (HS) are frequent consequences of dermal burn with a prevalence of 70% of burned people. HS, which are a dermal fibro-proliferation, are rigid, erythematous and thickened scars associated with pigmentation abnormalities, xerosis, thermal sensitivity, pain and pruritus.

When HS is located on the face, they can cause cosmetic disorder with disfigurement and psychological distress.

Pressure therapy and silicone application are the two recommended non-invasive care for prevention and treatment of hypertrophic scarring after burn. On the face, Pressure Garment Therapy (PGT) cannot exert the required pressure because of concave or flat shape so the use of face mask is the most common form of pressure therapy on the face.

The face mask manufacturing is artisanal, time consuming and variable between all burn centers. They are not very accurate and have difficulties to apply effective pressure on certain face areas such as nasolabial folds.

Our Transparent Face Orthosis (TFO) uses tri-dimensional cam for measurement and 3d-printing technology for manufacturing. We think this way to manufacture the TFO will be more accurate and efficient, less expansive and time consuming. Moreover, the addition of a silicone interface between the TFO and the face will associate silicone application therapy and pressure therapy what should be more effective than pressure therapy alone.

The purpose of this study is to assess the tolerance of tailored 3d-printed transparent face orthosis used in the medical care of post-burn face scar.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
13 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Device Feasibility
Official Title:
Tolerance Assessment of Tailored 3d-printed Transparent Face Orthosis With Silicone Interface for the Treatment of Post-burn Face Scar
Anticipated Study Start Date :
Oct 1, 2022
Anticipated Primary Completion Date :
Feb 1, 2025
Anticipated Study Completion Date :
Feb 1, 2027

Arms and Interventions

Arm Intervention/Treatment
Experimental: Post-Burn Face scar

Use of 3d printed TFO with silicone interface (COFIS 3D)

Device: COFIS 3D
Patient have to wear the COFIS 3D 20h a day for at least 6 month
Other Names:
  • 3d printed Transparent Face Orthosis with silicone interface
  • Outcome Measures

    Primary Outcome Measures

    1. Number of Local Side Effects [Month 1]

      wound, device related pain, rash, temporomandibular joint pain, dental pain, suffocating sensation

    Secondary Outcome Measures

    1. Evaluation of scar evolution with VSS [Month 1; Month 6; Month 12; Month 18; Month 24]

      Vancouver Scar Scale (VSS) assesses 4 variables: vascularity (range 0-3), height/thickness (range 0-3), pliability (range 0-5) and pigmentation (0-2). A total scores ranges from 0 to 13, whereby a score of 0 reflects normal skin.

    2. Evaluation of scar evolution with POSAS [Month 1; Month 6; Month 12; Month 18; Month 24]

      Evaluation of scar evolution by Patient and Observer Scar Assessment Scale (POSAS). It consists of two scales which assesses vascularity, pigmentation, thickness, relief, pliability, and surface area and it incorporates patient assessment of pain, itching, color, stiffness, thickness and relief. All items were evaluated on numerical rating scales ranging from 1 to 10 (with 10 indicating the worst score).

    3. Wearing time [Month 1; Month 6; Month 12; Month 18; Month 24]

      Diurnal and nocturnal wearing time in hours

    4. Manufacturing time [Month 1; Month 6; Month 12; Month 18; Month 24]

      Time of device's manufacturing

    5. Reprints [Month 1; Month 6; Month 12; Month18; Month 24]

      Number of reprints needed per patient

    6. Device lifetime [Month 1; Month 6; Month 12; Month18; Month 24]

      Device lifetime corresponds to the time between implementation and change of device (for any Reason) in days

    7. Evaluation of the quality of life with the BSHS-B [Month 1; Month 6; Month 12; Month 18; Month 24]

      Evaluation of the quality of life of patients by the BSHS-B (Burn Specific Health Scale - Brief). The BSHS-B consists of 40 items divided into four domains with nine subscales (heat sensitivity, affect, hand function, treatment regimens, work, sexuality, interpersonal relationships, simple abilities and body change). Items are answered on a 5-point Likert scale ranging from 0 (extremely) to 4 (not at all).

    8. Number of Local side effects [Month 6]

      wound, device related pain, rash, temporomandibular joint pain, dental pain, suffocating sensation

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Age ≥18 years

    • Post-Burn Face scar during maturation stage or surgical intervention on post-burn face scar during maturation stage

    • Patient agrees to shave beard if necessary for 3D camera measurement

    • Patient able to express informed consent

    • Affiliation to a social security scheme

    Exclusion Criteria:
    • Post burn face scar in the sequela stage

    • Patient with unbalanced photosensitive epilepsy

    • Patient with an unconsolidated fracture of the face's bones or skull

    • Patient with a known allergy to silicone

    • Pregnant or lactating women

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Centre Hospitalier Régional Metz-Thionville

    Investigators

    • Principal Investigator: Clémence DEFFINIS, MD, CHR Metz Thionville

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Centre Hospitalier Régional Metz-Thionville
    ClinicalTrials.gov Identifier:
    NCT04884789
    Other Study ID Numbers:
    • 2018-A03067-48
    First Posted:
    May 13, 2021
    Last Update Posted:
    Jul 14, 2022
    Last Verified:
    Jul 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Centre Hospitalier Régional Metz-Thionville
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 14, 2022